Novo Nordisk announced that the marketing application for its new drug carelin peptide and simeglutide injection for long-term weight management has been accepted by the State Drug Administration. The drug is a fixed-dose compound preparation composed of the long-acting pancreatin receptor agonist carrelin peptide and the GLP-1 receptor agonist simeglutide, which is injected subcutaneously once a week. These two ingredients work together on pathways related to appetite and weight regulation through different and complementary mechanisms of action.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.